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Abstract
Cirrhotic cardiomyopathy and the hyperdynamic syndrome are clinically important 
complications of cirrhosis, but their exact pathogenesis is still partly unknown. 
Experimental models have proven the cardiotoxic effects of bile acids and recent stud-
ies of their varied receptor- mediated functions offer new insight into their involve-
ment in cardiovascular dysfunction in cirrhosis. Bile acid receptors such as farnesoid 
X- activated receptor and TGR5 are currently under investigation as potential thera-
peutic targets in a variety of pathological conditions. These receptors have also re-
cently been identified in cardiomyocytes, vascular endothelial cells and smooth muscle 
cells where they seem to play an important role in cellular metabolism. Chronic chol-
estasis leading to abnormal levels of circulating bile acids alters the normal signalling 
pathways and contributes to the development of profound cardiovascular distur-
bances. This review summarizes the evidence regarding the role of bile acids and their 
receptors in the generation of cardiovascular dysfunction in cirrhosis.
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1  | INTRODUCTION
In patients with cirrhosis the course of the disease is determined by 
the development of severe complications due to the altered structure 
and metabolic function of the liver. Patients can develop splanchnic 
and arterial vasodilatation leading to an increase in heart rate and 
cardiac output defining the “hyperdynamic circulatory state”, as well 
as a chronotropic and inotropic cardiac incompetence termed “cir-
rhotic cardiomyopathy”.1 This profound cardiovascular dysfunction 
contributes to multiorgan failure in decompensated cirrhosis but its’ 
underlying pathogenesis is not fully understood. Exploration of the 
therapeutic opportunities presented by bile acid (BA) modulation in 
cholestatic disorders as well as in nonalcoholic fatty liver disease, 
obesity, diabetes and inflammatory bowel disease has imposed a new 
paradigm of bile acids as a signalling and metabolic crossroad.2 Thus, 
there is an abundance of data on the role of altered BA homeosta-
sis in diseases ranging from metabolic syndrome to tumorigenesis to 
cirrhosis.
Although both the cardiotoxic effect of BAs and the existence of 
a hyperdynamic syndrome in cirrhotic patients have been known for 
some time, there is relatively little data on the impact of BAs on cardio-
vascular function in the setting of chronic liver disease. The aim of this 
review was to provide a survey of the current evidence regarding the 
action of BAs on receptors and pathways relevant to the development 
of cardiovascular disturbances in cirrhosis.
2  | BILE ACIDS AND THEIR METABOLISM
Bile acids are products of the tightly regulated metabolism of choles-
terol by the liver. The cholic (CA) and chenodeoxycholic acid (CDCA) 
Abbreviations: BA, bile acid; BKCa, large conductance calcium-dependent potassium chan-
nels; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; eNOS, endothe-
lial nitric oxide synthase; FXR, farnesoid X-activated receptor; ICP, intrahepatic cholestasis of 
pregnancy; LCA, lithocholic acid; NFκB, nuclear factor κB; NO, nitric oxide; OCA, obeticholic 
acid; PBC, primary biliary cholangitis; Pgc1α, peroxisome-proliferator-activated receptor γ 
co-activator; PXR, pregnane X receptor; S1PR2, sphingosine-1-phosphate receptor-2; UDCA, 
ursodeoxycholic acid; VDR, vitamin D receptor.
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also known as “primary bile acids” are exclusively synthesized in hepat-
ocytes under enzymatic control with 7α- hydroxylation by CYP7A1 
as the main pathway and rate- limiting step.3 Once formed they are 
conjugated via an amide bond with an amino acid to increase hydro-
philia. The amphipathic glyco- or tauroconjugates are then secreted 
through canalicular bile- salt export pumps into the bile canaliculi and 
contribute to hepatocyte excretion and bile formation. Interprandially 
bile is stored in the gallbladder from where it is expelled into the small 
intestine during meal ingestion. Once it reaches the intestinal lumen 
bile mixes with the gastric chyme and emulsifies fat and fat- soluble vi-
tamins required for proper nutrient digestion and absorption. Ninety- 
five per cent of the BAs secreted are then reabsorbed in the terminal 
ileum via the apical sodium- dependent bile transporter present in the 
brush border membrane of the enterocytes.4 The remainder are con-
verted into “secondary bile acids”: deoxycholate (DCA) and lithocho-
late (LCA) and less than 1% to ursodeoxycholate (UDCA) by anaerobic 
bacteria in the colon and are either passively absorbed or excreted in 
the faeces. The absorbed BAs are delivered to the liver where some 
are actively transported back into hepatocytes closing the loop of the 
so- called “enterohepatic circulation” (Figure 1). BAs that reach the 
colon can be absorbed but 5% are lost in faecal output, while most of 
the BAs reaching the kidneys are reintroduced in circulation.5
The alteration of BA pool size and composition is a consequence 
of the disturbed metabolism in cirrhosis but it also contributes to the 
progression of liver disease. There is now increasing evidence of a 
causal relationship between reduced faecal BA concentrations, the 
gut microbiome and systemic inflammation.6,7 The low input and con-
version of primary BAs in the colon encountered in advanced cirrho-
sis leads to dysbiosis characterized by an alteration of the equilibrium 
between the main bacterial species normally inhabiting the large in-
testine.8 Overgrowth of intestinal bacteria and increased gut perme-
ability due to the insufficient antimicrobial function of a depleted BA 
pool is followed by bacterial translocation and a potent inflammatory 
response that can determine decompensation of liver disease.9 In a 
recent observational prospective study, increased BA levels correlated 
with acute decompensation on admission of cirrhotic patients inde-
pendently of sex, age and MELD score.10
Carefully regulated feedback loops that promote a stable BA pool 
have been identified in the last decades. The most important regu-
latory pathway is dependent on the Farnesoid X- activated receptor 
(FXR) expressed in the nucleus of both terminal ileum enterocytes and 
hepatocytes. FXR can reduce the BA pool by inhibiting the main syn-
thetic CYP7A1- regulated pathway either directly or through fibroblast 
growth factor 19 as well as by lowering the hepatocyte portal uptake 
of BAs through sodium- taurocholate cotransporting polypeptide.11
In cholestatic syndromes, serum BA concentration rises due to 
backflow or inefficient hepatocellular uptake illustrating a functional 
defect in bile formation at the level of the hepatocyte or impairment 
in bile secretion and flow. The accumulation of highly cytotoxic hydro-
phobic BAs12 in the hepatocytes induces up- regulation and recruit-
ment of alternative export pumps at the basolateral membrane in an 
attempt to evacuate the toxic molecules out of the cell and into the 
circulation with subsequent renal excretion offering some relief.13
Cholestasis is encountered in numerous hepatic and systemic dis-
orders14,15 and is a particularly common feature of cirrhosis. Based 
on Dame Sheila Sherlock’s16 initial observations of increased serum 
BAs in liver disease, further efforts in the 1970s17-19 established that 
up to a 100- fold increase in concentrations is encountered in cir-
rhosis. Hence, cirrhotic patients can have serum concentrations well 
above 100 μmol/L,20,21 whereas the normal range of bile acids in 
fasting human adults is 2- 15 μmol/L depending on age and gender.22 
Furthermore, there also appears to be a shift towards lower ratios of 
the trihydroxy to dihydroxycholanic acids as well as glycine to tau-
rine conjugates. So far, however, the lack of significant diagnostic or 
prognostic benefit has discouraged the adoption of serum BA mea-
surement as part of the routine work- up in patients with liver disease.
3  | BILE ACID RECEPTORS IN CARDIAC  
AND VASCULAR CELLS
The discovery in 1995 of a new type of nuclear hormone receptor, 
the Farnesoid X- activated receptor,23 and the search for its natural 
ligand led to the surprising conclusion that endogenous BAs were also 
potent signalling molecules that regulate cholesterol metabolism and 
their own synthesis.24 FXR is activated by hydrophobic BAs: CDCA 
followed by LCA, DCA and CA and is essential to the regulation of 
the BA pool. Further studies have revealed other BA- responsive el-
ements: nuclear receptors (pregnane X receptor- PXR,25 vitamin D 
receptor- VDR26), G- protein coupled receptors (muscarinic recep-
tors – M2, M3, TGR5, sphingosine- 1- phosphate receptor- 2- S1PR2
27), 
calcium- activated potassium channels and α5β1 integrin.28 These re-
ceptors are primarily expressed by gastrointestinal tissues but some 
have also recently been identified in cardiomyocytes, endothelium 
and vascular smooth muscle cells,29,30 which has led to speculation on 
possible cardiovascular effects of bile acids.
Ligand- bound nuclear receptors undergo conformational changes 
and dimerization to interact with specific DNA regions and in-
duce gene transcription. FXR is currently the best characterized 
BA- responsive nuclear receptor and studies have shown its’ role in 
Key points
• Cardiovascular dysfunction is prevalent in chronic chole-
static syndromes and cirrhosis.
• Bile acids directly and reversibly affect cardiac function in 
experimental models of cholestasis and cirrhosis.
• Through action on specific receptors bile acids influence 
metabolism, function, growth and survival of cardiomyo-
cytes, vascular endothelial cells and smooth muscle cells.
• The similar pathogenetic mechanisms described in cardio-
vascular dysfunction in cirrhotic patients argue for the 
role of bile acids in the development of cirrhotic 
cardiomyopathy.
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regulation of bile acid homeostasis, glucose and lipid metabolism, en-
ergy expenditure and inflammation. The finding that synthetic FXR 
ligands can inhibit interleukin- 1β- induced inflammatory responses in 
rat aortic smooth muscle cells pleads for the antiatherogenic poten-
tial of FXR agonists.31 The putative mechanism of this effect is the 
tethering transrepression of nuclear factor κB (NFκB) by the acti-
vated FXR with subsequent antagonization of this proinflammatory 
pathway.32 Using an automated high- throughput luciferase assay, 
Bijsmans et al.33 identified the glucocorticoid mometasone fumoate 
as a potent inhibitor of the TNFα- induced transcriptional activity of 
NF- κB. Showing that the proinflammatory cascade can be selectively 
inhibited without undue simultaneous influence on metabolic target 
genes is an important step in designing an FXR-targeted drug with 
anti- inflammatory properties.
This finding is extremely promising in the setting of our current 
knowledge of the pathogenesis of cirrhotic cardiomyopathy. Valuable 
work produced by Lee and his group in the last decade has convinc-
ingly established a pathogenetic link between bacterial translocation 
or endotoxemia and increased activity of an endocannabinoid- TNFα- 
NFκB axis leading to reduced cardiac contractility in animal mod-
els.34,35 Study of TNFα knockout bile duct ligated mice offered insight 
into the complex interplay between the effects of local endocanna-
binoid and TNFα release and cardiac inotropism.36 Bile duct ligated 
animals showed depressed cardiac function and increased expres-
sion of TNFα and NFκB while treatment with anti- TNFα antibodies 
significantly improved cardiomyocyte contractility. There is also new 
evidence supporting the role of FXR in regulating vascular contractile 
response and blood pressure. In a recent study, treatment with CDCA 
F IGURE  1 Bile acid metabolism. Cholic acid (CA) and chenodeoxycholic acid (CDCA) are synthesized from cholesterol via a main pathway 
controlled by the rate- limiting enzyme CYP7A1. After conjugation with glycine or taurine they are excreted via the canalicular bile- salt export 
pump (BSEP) to form bile. 95% of bile acids (BA) are absorbed actively upon reaching the terminal ileum through the apical sodium- dependent 
bile- salt transporter (ASBT). They are excreted through organic solute transporter α and β dimer (OSTα/β) located on the basolateral enterocyte 
into the portal circulation from where they are absorbed by hepatocytes via the sodium-taurocholate cotransporting polypeptide (NTCP) and 
organic anion transporters (OATP1. BAs reaching the colon are deconjugated and dehydroxylated by bacteria and form “secondary BAs” (mainly 
deoxycholic acid – DCA and lithocholic acid – LCA) which can be absorbed or pass into stool. The Farnesoid X- activated receptor (FXR) reduces 
BA synthesis by inhibiting CYP7A1 directly or through fibroblast growth factor 19 (FGF19) and lowers hepatocyte portal uptake of BAs through 
NTCP. MRP2, Multidrug resistant associated protein; OATP, Organic anion transporter protein
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for 8 weeks of spontaneously hypertensive rats resulted in vasorelax-
ation and lower blood pressure and this correlated with a significant 
reduction in NFκB activity in the mesenteric arteries.37
Using cultured cardiomyocytes Pu et al. demonstrated that FXR 
is expressed in cardiac cells and that its’ activation causes significant 
apoptosis through mitochondrial death signalling. They also verified 
their findings in an in vivo mouse model of myocardial ischaemia/
reperfusion injury and concluded that FXR signalling could be involved 
in several cardiac diseases related to cardiomyocyte growth and apop-
tosis.38 The indications that FXR may lower plasma triglyceride levels, 
regulate peripheral insulin sensitivity and protect against atheroscle-
rosis,39 make a very strong case for current attempts at therapeutic 
intervention on this receptor in patients suffering from metabolic 
syndrome. While PXR and VDR play important parts in BA and drug 
metabolism and detoxification, less is known of their effects on vas-
cular homeostasis.40 Green et al.41 studied the effect of vitamin D(3) 
on sarcomere shortening and relaxation in adult rat myocytes and de-
scribed an acute decrease in peak shortening coupled with an increase 
in contraction rate, but only accelerated relaxation persisted under 
chronic stimulation. This rapid nongenomic response could be due to 
a membrane- associated VDR that regulates calcium influx into the car-
diomyocytes resulting in modulation of diastolic function.42
Bile acids can also functionally interact with membrane receptors 
and activate intracellular effector cascades. Discovery of a structural 
similarity between taurolithocholate and acetylcholine led to interest 
in the interaction between BAs and muscarinic receptors, with reports 
revealing an antagonistic effect of DCA on M2 and M3 receptors also 
expressed in cardiac tissue.43 In this study, Raufman et al. compared 
the effect of BAs to other muscarinic blockers on Chinese hamster 
ovary cells expressing rat M3 receptors and found that DCA and its’ 
conjugates act as muscarinic antagonists at levels normally encoun-
tered in human bile. Such an effect would result in a reduction in in-
tracellular levels of cyclic adenosine monophsophate which negatively 
influences chronotropism.
Observations related to the reduced cell- mediated immunity and 
macrophage functions in cholestasis led to the identification of a novel 
cell- surface- based signalling pathway for BAs: the G- protein coupled 
TGR5 identified in macrophages but also in the heart, skeletal muscle, 
spleen, kidney, liver, small intestine and placenta.44 The deleterious ef-
fect of prolonged exposure of immune cells to increased levels of BAs 
indicatesthat they may be a mediator of the increased risk of infectious 
complications and endotoxemia frequently encountered in cirrhosis. 
TGR5 seems to be integral to the control of inflammasome NLRP3 
activation by BAs, a process required to develop the proinflamma-
tory response to pathogen- associated molecular patterns.45 While its’ 
exact effect is still debated due to contradictory results in different ex-
perimental models, there is substantial evidence supporting the action 
of CDCA on the TGR5- NLRP3 axis.38,46 Another pathway by which 
BAs may contribute to the pathogenesis of hyperdynamic circulation 
in cirrhosis was proposed by Fiorucci et al. who showed that LCA but 
not CDCA activates endothelial TGR5 to increase cystathionin γ- lyase- 
dependent generation of vasodilatatory hydrogen sulphide.47 TGR5 
activation by BAsis also involved in metabolic switching from fatty acid 
to glucose oxidation in cardiac cells as well as increasing energy expen-
diture in brown adipose tissue,48 a function which is intriguing consid-
ering the role played by cachexia in the outcome of cirrhotic patients.
Another G- protein coupled receptor that has proven sensitive to 
BAs is the sphingosine- 1- phosphate receptor- 2. Conjugated BAs acti-
vate S1PR2 which acts through ERK1/2 and AKT signalling pathways 
to regulate hepatic glucose and lipid metabolism.49 The interaction 
between BAs and sphingosine- 1- phosphate receptors is worthy of re-
search due to the involvement of S1PR- mediated pathways in hepatic 
myofibroblast motility and liver fibrogenesis50 as well as angiogenesis 
and vascular cell maturation.51
Bile acids have also been shown to increase the activity of large 
conductance calcium- dependent potassium channels (BKCa) located in 
smooth muscle cells. Dopico et al.52 speculate that the reversible BA- 
induced systemic vasodilation seen in hepatobiliary diseases could be 
due, at least in part, to activation of BKCa and subsequent relaxation of 
vascular smooth muscle cells. LCA was also shown to induce vasodila-
tion and a 30% increase in blood flow in cerebral resistance arteries in 
an endothelium- independent fashion but this effect was abrogated in 
BK β- 1 subunit knockout mice models, underlining the role of this sub-
unit of potassium channels in BA- dependent activation of ion flow.53 
Since vasodilation and increased flow are essential components of the 
hyperdynamic syndrome, these findings argue for a receptor- mediated 
BA involvement in the persistance of this haemodynamic complication 
of cirrhosis.
4  | BILE ACIDS AND CARDIOVASCULAR  
FUNCTION
4.1 | Cardiac effects
The initial observation of a deleterious effect of bile on the cardiac 
function dates back to the 19th century. Intravenous injection of BAs 
in animal specimens induced profound bradycardia and, in high doses, 
even cardiac arrest despite heart denervation.54 Further studies con-
firmed a direct arrhythmogenic response of the heart to exposure to 
supraphysiological levels of BAs as such encountered in cholestasis. 
Joubert demonstrated a dose- dependent negative chronotropic ef-
fect of cholic acid,55 but it took several years until the precise cellular 
mechanism was elucidated. Working on papillary muscle and isolated 
ventricular myocytes Binah et al.56 reported that sodium taurocholate 
decreased the slow inward sodium and calcium current and slightly 
increased the outward potassium current, thus reducing action poten-
tial duration, inotropism and chronotropism.
A lot of interesting work in the field of bile acid effects on car-
diac tissue is a direct consequence of observations regarding the high 
rate of foetal complications and stillbirths associated with intrahepatic 
cholestasis of pregnancy (ICP).57-59 Starting from reports of foetal ar-
rhythmias in obstetric cholestasis Williamson and Gorelik proposed 
that impaired foetal cardiomyocyte function leading to intra- uterine 
death could be due to the high levels of BAs present in patients with 
ICP.60 Their initial report revealed that taurocholate altered calcium 
dynamics which led to loss of synchronous beating of cardiomyocytes. 
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The same group showed that taurocholic acid was responsible for re-
duced contractility and pacemaker activity61 while ursodeoxycholic 
acid protected against reentrant arrhythmias by modulating potassium 
conductance.62,63
Due to the difficulties of conducting studies in the setting of ICP, 
such conclusions are mainly based on cell- cultures and animal mod-
els with few studies looking into the arrhythmogenic effects of BA 
in humans.64 Rainer et al.65 showed that taurocholic acid- induced 
concentration- dependent arrhythmia in human atrial myocardium and 
noted an association between atrial fibrillation and higher serum levels 
of nonursodeoxycholic bile acid conjugates and low levels of ursode-
oxycholic acid conjugates in 250 patients. This reinforces the concept 
that bile acid composition and not only the increased concentration is 
important.66
The accumulating evidence of the bile acid alteration of cardiac 
function in cholestasis has led to the hypothesis that BAs may play 
a major role in the pathogenesis of cardiomyopathy in cholestatic 
liver diseases.67 Based on evidence of their negative inotropic and 
chronotropic effects, Gazawi et al.68 showed that BAs also adversely 
affect cardiac β- adrenoceptor density and affinity and membrane 
fluidity, modifications which have also been described in cirrhotic 
cardiomyopathy. A comprehensive summary of the various factors 
that mediate the effects of BAs on cardiovascular tissues from ex-
perimental animal models has been presented by Khurana et al.69 
However, despite identification of several BA- sensitive receptors 
(FXR, VDR, TGR5, M2) in cardiomyocytes, proof of their function is 
mainly indirect and a definitive pathogenetic mechanism has not yet 
been formulated.
4.2 | Vascular effects
The abnormally high levels of bile acids in the circulation encountered 
in cholestatic and chronic liver disease also have a direct effect on the 
function of endothelial and vascular smooth muscle cells with poten-
tial haemodynamic consequences.
Creation of a choledochocaval anastomosis in dogs resulted in 
a decrease in mean arterial pressure and peripheral vascular resis-
tance but with preserved mean cardiac index and plasma volume.70 
Bile duct ligation was shown to reduce the vascular smooth muscle 
contractile response to noradrenaline with DCA being the most po-
tent inhibitor.71 Pak et al.72 elegantly tried to identify the pathoge-
netic mechanisms by pharmacologically blocking membrane pumps, 
ion channels, adrenoceptors and sensory afferent nerves in rat iso-
lated portal venous and superior mesenteric arterial specimens. 
Incremental doses of BAs induced vasorelaxation irrespective of 
blocking agents or denudement of the endothelium showing that 
the action is probably mediated through inhibition of calcium entry 
through membranary channels. This is highly influenced by the type 
of bile acid and indeed it seems that hydrophobic and lypophilic BAs 
are more likely to induce vasorelaxation.73 The authors speculated on 
the mechanism by which bile acids accomplish this effect and con-
cluded that it must be through direct interaction with components of 
the cellular membrane.
Again, the discovery and characterization of previously unknown 
bile acid receptors changed our understanding of how BAs induce 
vasodilation. Attention turned towards FXR due to its’ recent iden-
tification in vascular endothelial and smooth muscle cells. Because 
of its’ function as a transcription factor, it was to be expected that 
activated FXR regulates vasomotricity by altering the expression of 
vasoactive molecules and other receptors. Studies have shown that 
it can downregulate endothelin- 1 and upregulate endothelial nitric 
oxide synthase (eNOS) in endothelial cells,74,75 modulate angioten-
sin- II receptor expression and inhibit vascular smooth muscle cell in-
flammation and migration.76 After proving the functionality of FXR in 
pulmonary endothelial cells He et al.74 demonstrated that activation 
by CDCA results in a decreased expression of endothelin- 1 mRNA in 
a concentration- dependent manner. Since endothelin- 1 is the most 
potent known vasoconstrictor its’ repressed expression due to BAs 
could be an important contributor to the systemic vasodilation present 
in cirrhosis. The same group later proposed the existence of a FXR- 
responsive element in the promoter region of eNOS, the activation of 
which resulted in upregulation of eNOS and subsequent increase in 
production of the vasodilatatory nitric oxide (NO).75 S1PR2 is another 
BA- sensitive receptor found on vascular smooth muscle cells involved 
in NO signalling, but it acts by inhibiting the inducible nitric oxide syn-
thase and thus lowering local NO levels in vascular injury.77-79
4.3 | Lessons learnt from therapy: ursodeoxycholic 
acid and obeticholic acid
Further evidence of the impact of BAs on cardiovascular function can 
be inferred from reports of ursodeoxycholate in experimental mod-
els as well as human studies. Since its’ introduction in clinical prac-
tice UDCA has mainly been used in the treatment of primary biliary 
cholangitis80,81 and intrahepatic cholestasis of pregnancy. UDCA is a 
highly hydrophilic bile acid that improves biological parameters and 
histological features and delays progression to cirrhosis and the time 
to liver transplantation and was, until recently, the only approved 
therapy for primary biliary cholangitis (PBC).82,83 The mechanism of 
action has long been a matter of debate, but it is beyond a doubt 
that UDCA is a potent signalling molecule which modulates cholan-
giocytic bicarbonate secretion and intracellular calcium availability 
but also activates various kinases resulting in antiapoptotic and anti- 
inflammatory effects.84-86
The first exploration of the cardiohaemodynamic impact of UDCA 
in patients with cirrhosis was predicated on its’ suspected diuretic and 
natriuretic properties compared to hydrophobic bile acids. Bomzon’s 
group administered therapeutic doses of UDCA for 1 month to pa-
tients with PBC and postnecrotic cirrhosis and used blood pressure, 
heart rate, two- dimensional and pulsed Doppler echocardiography 
to measure cardiac function. They reported a decrease in diastolic 
volume in PBC patients and slightly lowered cardiac output in post-
necrotic cirrhotic patients, with no change in heart rate or blood pres-
sure.87 It is worth noting that only half of the patients with PBC were 
cirrhotic while the postnecrotic viral hepatitis B or C patients all had 
significantly lower mean arterial blood pressure at baseline.
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The same hypothesis was tested in patients with refractory ascites, 
half of them with TIPS, in the hope that UDCA would reduce vasodi-
lation and improve renal sodium handling. Radionuclide angiography 
and venous occlusion plethysmography were used to ascertain central 
blood volume and total forearm blood flow respectively. There was 
no change in these systemic haemodynamic parameters, heart rate or 
mean arterial pressure during or after the end of the treatment, but the 
authors noted a decrease in sodium clearance and weight gain in all 
patients, concluding that UDCA led to sodium retention.88
More recent studies have yielded similarly conflicting results. Thus, 
Schiedermaier et al.89 reported a decrease in diastolic blood pressure 
but not portal flow in a small human cross- over study, while Yang 
et al.90 described a reduction in portal pressure due to diminished in-
trahepatic resistance in a rat model. A nitric oxide- delivering derivative 
of UDCA was also shown to ameliorate portal hypertension without 
affecting arterial pressure.91
The impact on cardiac function has not been well studied but there 
is evidence that UDCA exerts limited but positive effects on periph-
eral blood flow in heart failure,92 prevention of ischaemia- reperfusion 
injury and apoptosis,93 as well as acute cardiac rejection in the post- 
transplant setting.94
The limited effect of UDCA in cholestatic conditions led to the 
search for new therapeutic agents.95 Obeticholic acid (OCA) was syn-
thesized from CDCA as a selective potent FXR agonist with anticholes-
tatic properties.96 It was hoped that OCA might supersede UDCA and 
represent an alternative for patients with primary biliary cholangitis 
not responding to first- line treatment. Cautiously optimistic improve-
ment in composite endpoints was noted in two randomized, double- 
blind, placebo- controlled trials after 12 months of treatment97,98 
which has led to the accelerated FDA approval of OCA for treatment 
of PBC.99 Studies are also underway in primary sclerosing cholangitis, 
nonalcoholic steatohepatitis,100 severe alcoholic hepatitis, portal hy-
pertension and bile acid- induced diarrhoea.
Recently, there have been several exciting reports regarding the 
effect of obeticholic acid on the portal circulation. In both cholestatic 
and noncholestatic cirrhotic rat models, OCA improved ileal barrier 
function, reduced bacterial translocation and gut immune cell infiltra-
tion.101-103 Verbeke et al.104 showed that cirrhotic rats receiving OCA 
had a mean portal pressure 15%- 21% lower than controls without a 
decrease in mean arterial pressure, thus suggesting a liver- specific 
effect of OCA most probably due to increased intrahepatic eNOS ac-
tivity. This lack of effect on the systemic circulation does not seem to 
indicate obeticholic acid use in the setting of cirrhotic cardiomyopathy, 
but systemic haemodynamic effects with a longer treatment period 
are conceivable and FXR modulation could turn out to be the “mo-
lecular master switch” for cirrhosis progression.105 Some evidence of 
the therapeutic capabilities of OCA on extrahepatic vasculature comes 
from a model of induced pulmonary hypertension in which OCA treat-
ment counteracted fibrosis and endothelial/mesenchymal transition 
and exerted cardiopulmonary protective effects.106 Whether similar 
benefits can be expected in reducing the deleterious effects of hyper-
dynamic syndrome or even portopulmonary hypertension in cirrhosis 
is debatable.
5  | BILE ACIDS AND THEIR RELATIONSHIP 
WITH CIRRHOTIC CARDIOMYOPATHY
A profound and chronic state of cardiovascular dysfunction has been 
a well- known manifestation of decompensated cirrhosis for more 
than 60 years.107 Cirrhotic patients develop arterial vasodilation and 
redistributionof the circulating blood volume with ensuing central 
hypovolaemia caused by increases in hepatic vascular resistance and 
splanchnic pooling of blood.108 The identification of this veritable hy-
perdynamic syndrome encouraged further study of the cardiac effects 
of advanced liver disease. The pattern of cardiac functional and struc-
tural alterations noted irrespective of aetiology or severity of cirrhosis 
developed into a novel concept named “cirrhotic cardiomyopathy”. 
The currently accepted definition of this complication of cirrhosis re-
quires evidence of systolic and/or diastolic dysfunction, the presence 
of electromechanical disturbances and changes in levels of serological 
markers of cardiomyocyte injury in the absence of concurrent cardiac 
pathology.109 This generally entails 2D echocardiography, electro-
cardiography and measurement of pro- brain natriuretic peptide or 
Troponin levels, however, more advanced and accurate techniques 
such as tissue Doppler imaging, speckle tracking and cardiac magnetic 
resonance imaging are increasingly being used.110,111 While the best 
diagnostic algorithm and cut- off for the various parameters are still 
under evaluation, cirrhotic cardiomyopathy has been shown to be 
clinically relevant in this population of fragile patients.112-117 Stressful 
events that further alter the haemodynamic balance such as insertion 
of TIPS, liver transplantation or sepsis provoke the transformation of 
the normally latent cardiac dysfunction into overt heart failure with 
severe systemic consequences such as the development of hepatore-
nal syndrome.118,119 Reversal of cardiac dysfunction is normally seen 
in the first 6- 12 months after liver transplantation.120
Various vasoactive substances and pathways have been shown 
to be involved in the pathogenesis of cardiovascular dysfunction in 
cirrhosis.121 In experimental models of cirrhosis, cardiomyocytes 
evince reduced membrane fluidity, perhaps due to a direct action of 
bile acids,68 which leads to altered β- adrenergic receptor function 
and density.122 An inadequate response to adrenergic stimulation is 
one of the main features that define our current understanding of 
cirrhotic cardiomyopathy. A blunted response to muscarinic M2 and 
M3 receptors located in cardiac as well as vascular endothelial cells 
has also been noted in cirrhosis123 and this is in accordance with the 
described effect of DCA on such receptors.43 The main role of mem-
brane receptor- signalling regards regulation of intracellular potassium 
and calcium concentrations which impacts the duration of the action 
potential and thus inotropism and lusitropism.124
Recent advances in characterizing the metabolism and actions of 
nitric oxide have led to a deeper understanding of the importance of 
this molecule in the pathogenesis of the hyperdynamic syndrome in 
cirrhosis.34 NO is synthesized in endothelial cells and cardiomyocytes 
and is involved in vasodilation, inotropic and chronotropic cardiac im-
pairment through a variety of mechanisms. The increased formation 
of NO in cirrhosis may be due to bacterial translocation with endotox-
emia that results in macrophage activation and increased expression 
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of tumour necrosis factor α.125 Carbon monoxide, endocannabinoids 
and inflammatory cytokines also play a role as vasoactive and cardio-
depressant agents in this setting.126,127
This variety of molecules with different and often opposite actions 
argues for the existence of multiple and complex pathways to cardio-
vascular dysfunction in cirrhosis, precluding a unique pathogenetic 
agent (Figure 2). It is intriguing that so many of the aforementioned 
pathways have recently been shown to be influenced or regulated 
by bile acids. Initial in vitro and in vivo studies also suggest that BAs 
could be involved in splanchnic hyperaemia and circulatory dysfunc-
tion leading to the hyperdynamic syndrome.128 However, so far, there 
have been few studies specifically aimed at defining the interactions 
between bile acids and cardiovascular function in cirrhosis.
By incubating isolated heart mitochondria with BAs at toxico-
logically relevant concentrations, Ferreira proved that hydrophobic 
BAs significantly alter mitochondrial bioenergetics in conditions 
similar to those encountered in cholestasis.129 Zavecs and Battarbee 
have shown that acute exposure of cardiac muscle to cholic acid 
mimics several characteristics of cardiac dysfunction observed in 
cirrhotic rat models including depressed β- adrenoceptor- mediated 
inotropism and decreased depolarization- dependent calcium entry. 
Furthermore, replacing lipophilic BAs with UDCA reduces cardiac 
impairment.130 By obtaining similar results in cirrhotic and noncir-
rhotic portal vein stenosis models, their results suggest that bile 
acids themselves are significant factors in the genesis of cirrhotic 
cardiomyopathy.
F IGURE  2 The effects of bile acids on the main cellular pathways involved in cardiovascular homoeostasis. Elevated bile acid (BA) levels 
affect the function and metabolism of cardiomyocytes (CM), vascular endothelial cells, VSMC (vascular smooth muscle cells) and circulating 
macrophages. BAs open large conductance calcium- dependent potassium channels (BKCa) on CM and VSMC resulting in increased outward 
potassium ([K+]o) current.52 Membrane fluidity is also directly reduced as are sodium and calcium entry, leading to decreased action potential 
duration, decreased chronotropism and inotropism and an increased risk of arrhythmias.55,56 BAs are antagonists of muscarinic receptors (M2, 
M3) located on CM and VSMC but they also affect β- adrenoceptor (β- rec) membrane density and responsiveness.43,68,121 Receptors like TGR5 
and sphingosine- 1- phosphate receptor- 2 (S1PR2) activate metabolic switching due to reduced peroxisome- proliferator- activated receptor γ co- 
activator (Pgc1α) expression and altered protein kinase function (AKT, GSK3β).131,132 BA action is responsible for vasodilation through reduction 
in endothelin- 1 expression (ET- 1) and modulation of inducible (iNOs) and endothelial (eNOS) nitric oxide synthase.74,75,77 BAs also affect 
inflammatory response to circulating bacterial lipopolysaccharides (LPS).8,9 COX- 2, Cyclooxygenase; AT2R, angiotensin II receptor; FAO, fatty 
acid oxidation; cAMP, cyclic adenosinemonophosphate
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Further proof of this relationship was provided by Desai et al.131 by 
comparing RNA and protein expression in heart tissue from a model 
of biliary fibrosis with cardiomyocyte cell cultures treated with tauro-
chenodeoxycholic or litocholic acid. The authors documented similar 
myocardial hyperthrophic signalling reminiscent of cirrhotic cardiomy-
opathy in both cases.
Recently, the same group elegantly demonstrated that high serum 
BA levels were associated with increased ejection fraction and short-
ening fraction of the left ventricle but lower heart rate.132 Furthermore, 
they demonstrated that the foetal gene expression of hypertrophic 
signals as well as electrocardiographic and ultrasonographic features 
of cardiomyopathy resolve with reversal of liver injury. The authors 
proposed a new term “cholecardia” to describe the cardiodepressant 
effects of BAs and they used a double knockout model (Fxr−/−; Shp−/−) 
to show similarities between experimental severe bile acid overload 
and human cirrhotic cardiomyopathy. Analysis of the metabolic switch 
from fatty acid to glucose oxidation encountered in cardiomyocytes 
exposed to bile acids led to the conclusion that reduced peroxisome- 
proliferator- activated receptor γ co- activator (Pgc1α) expression 
affects cardiac performance. Both overexpression of Pgc1α in cardio-
myocytes and administration of BA- binding cholestyramine reduced 
the detrimental effects of hydrophobic BAs on cardiac function. These 
results convincingly argue for a direct and reversible effect of bile acids 
on cardiomyocytes.133
6  | CONCLUSION
Experimental models continue to improve and they have significantly 
increased our understanding of the relationship between bile acids 
and cardiovascular dysfunction, but they do not perfectly mirror the 
clinical experience of cirrhotic cardiomyopathy. The current wealth 
of data generated by the recent interest in FXR modulation of me-
tabolism and its’ therapeutic possibilities would indicate a major role 
for this receptor in the pathogenesis of cirrhotic cardiomyopathy. 
However, when considering that the cardiovascular and metabolic 
profile encountered in cirrhosis has not been perfectly replicated in 
experimental models so far, the information we have is still lacking. 
Future efforts should be dedicated to deciphering the complex inter-
actions between bile acids and their various receptors. In addition, en-
ergy should also be directed towards assessment of the concentration 
and composition of the bile acid pool in various populations and their 
relationship with cardiovascular dysfunction in cirrhosis.
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